FlandersBio on Twitter

Galapagos NV: business update: http://t.co/6w1jppWE

Follow us on Twitter

stock market - News

stock market - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Cryo-Save Group N.V.: Dividend Proposal +14%

07.02.2012

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international family stem cell bank, announces that the Board plans to propose a dividend of €0.08 per share for the year ended 31 December 2011 (2010: €0.07) , a 14% increase on last year. read more

Ablynx statement on press article and related share price movements

23.01.2012

Ablynx [Euronext Brussels: ABLX] issued the following statement today. On Friday January 20th at 16.30 C.E.T., De Tijd, a Belgian newspaper, published online what was alleged to be a summary of a full article relating to Ablynx, scheduled to appear in print on Saturday January.21st. The online summary contained a number of negative statements and quotations apparently resulting from an interview with Dr Edwin Moses, Chairman and CEO of Ablynx. These statements and quotations were poorly translated or simply not reflective of the interview that took place. Ablynx's stock price fell almost 14% in about an hour and over 400,000 shares were traded in total - two to three times the normal volume. A number of investors that contacted Ablynx directly were clearly completely misled by the summary article and assumed that disappointing news had been announced. In fact, no material new information had been provided during the interview with De Tijd. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print